Beam Therapeutics Inc. (BEAM) intrinsic value & 10-year financials
Beam Therapeutics Inc. (BEAM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 345.0% a year to $139.7M, with an average return on invested capital of 93.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $23.47
- Market cap
- $2.3B
- Revenue (FY2025)
- $139.7M
- Revenue growth (8-yr CAGR)
- 345.0%
- ROIC (10-yr avg)
- 93.1%
- Free cash flow (FY2025)
- -$360.0M
BEAM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $139.7M | -$80.0M | -$0.81 | -$360.0M | -274.6% | -45.6% |
| FY2024 | $63.5M | -$376.7M | -$4.58 | -$356.2M | -654.3% | -63.7% |
| FY2023 | $377.7M | -$132.5M | -$1.72 | -$182.9M | -46.7% | -25.7% |
| FY2022 | $60.9M | -$289.1M | -$4.13 | -$26.4M | -555.6% | -63.0% |
| FY2021 | $51.8M | -$370.6M | -$5.77 | -$113.1M | -757.0% | -133.2% |
| FY2020 | $24.0K | -$194.6M | -$4.19 | -$112.1M | -553166.7% | 947.3% |
| FY2019 | $18.0K | -$78.3M | -$2.01 | -$84.5M | -417522.2% | 35.3% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Beam Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Beam Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -40.9% ROIC.
Beam Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Beam Therapeutics Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-26.90 per share.